ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg sol
RC-P0055
Approved small_molecule active
Quick answer
ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, RoActemra 162 mg solution for injection in pre-filled syringe., ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg solution for injection in pre-filled syringe, ORENCIA 125 mg sol for Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments. is a Approved program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments.
- Phase
- Approved
- Modality
- small_molecule
- Status
- active